Polypharmacy in HIV: Impact of data source and gender on reported drug utilization

AIDS Patient Care and STDs

Volumn 18, Issue 10, 2004, Pages 568-586

  Furler, Michelle D ^a   Einarson, Thomas R ^a,b   Walmsley, Sharon ^c,d   Millson, Margaret ^a   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ACETYLCYSTEINE; ANALGESIC AGENT; ANTIANEMIC AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE; CANNABIS; COCAINE; CODEINE; DIAMORPHINE; GLYCERYL TRINITRATE; HERBACEOUS AGENT; INSULIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPERAMIDE; MINERAL; MULTIVITAMIN; PARACETAMOL; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRICHOSANTHIN; UNINDEXED DRUG; VITAMIN; ZIDOVUDINE;

ADULT; AGED; AWARENESS; CANADA; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTION; OUTPATIENT; PHYSICIAN ATTITUDE; PILL; PNEUMOCYSTIS CARINII; POLYPHARMACY; PRESCRIPTION; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPLEMENTARY THERAPIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUGS, NON-PRESCRIPTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ONTARIO; OUTPATIENT CLINICS, HOSPITAL; POLYPHARMACY; PREVALENCE; SEX DISTRIBUTION; STREET DRUGS;

EID: 7244224745     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2004.18.568     Document Type: Review

References (56)

1. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S123-S127.
2. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 2001;28:124-131.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
4. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S112-S117.
5. Greenblatt RM, Hollander H, McMaster JR, Henke CJ. Polypharmacy among patients attending an AIDS clinic: Utilization of prescribed, unorthodox, and investigational treatments. J Acquir Immune Defic Syndr 1991;4:136-143.
6. Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatry 2003;160:547-554.
7. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-728.
8. Asch SM, Gifford AL, Bozzette SA, et al. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States. J Acquir Immune Defic Syndr 2001;28:340-344.
9. Augenbraun M, Tarwater P, Greenblatt R, et al. Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr 2001;28:195-196.
10. Dansak DA. Medical use of recreational drugs by AIDS patients. J Addict Dis 1997;16:25-30.
11. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS 2003;17:155-168.
12. Standish LJ, Greene KB, Bain S, et al. Alternative medicine use in HIV-positive men and women: Demographics, utilization patterns and health status. AIDS Care 2001;13:197-208.
13. Wootton JC, Sparber A. Surveys of complementary and alternative medicine: part III. Use of alternative and complementary therapies for HIV/AIDS. J Altern Complement Med 2001;7:371-377.
14. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDs 2004;18:215-228.
15. Piette JD, Fleishman JA, Stein MD, Mor V, Mayer K. Perceived needs and unmet needs for formal services among people with HIV disease. J Commun Health 1993;18:11-23.
16. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care 1992;30:17-29.
17. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res 1993;28:543-561.
18. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991;6:35-40.
19. Fleishman JA, Hsia DC, Hellinger FJ. Correlates of medical service utilization among people with HIV infection. Health Serv Res 1994;29:527-548.
20. Colebunders R, Schrooten W, Dreezen C, et al. Antiretroviral treatments used among adults with HIV infection in Europe. AIDS Care 2001;13:5-14.
21. Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDs 2002;16:233-240.
22. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health 2002;92:852-857.
23. Smith SR, Kirking DM. The effect of insurance coverage changes on drug utilization in HIV disease. J Acquir Immune Defic Syndr 2001;28:140-149.
24. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003;32:452-461.
25. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med 2000;160:3114-3120.
26. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999;281:2305-2315.
27. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. N Engl J Med 2001;344:817-823.
28. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000;24:475-482.
29. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003;32:499-505.
30. Pezzotti P, Pappagallo M, Phillips PN, et al. Response to highly active antiretroviral therapy according to duration of HIV infection. J Acquir Immune Defic Syndr 2001;26:473-479.
31. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol 1989;129:233-248.
32. Saunders K, Simon G, Bush T, Grothaus L. Assessing the feasibility of using computerized pharmacy refill data to monitor antidepressant treatment on a population basis: A comparison of automated and self-report data. J Clin Epidemiol 1998;51:883-890.
33. Health Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2002. Ottawa, Ontario, Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada; 2003.
34. Millson P, Leeb K, Cameron B, Major C, Palmer R, HOOD. Assessing representativeness in the HIV Ontario observational database - What is population-based research anyway? [Abstract Tu.C.48050]. International Conference on AIDS 1996;11:377.
35. Forte T, Bayoumi AM, Remis RS, et al. Representatives of the HIV Ontario Observational Database (HOOD) [Poster]. Canadian Association for HIV Research (CAHR) Halifax, Nova Scotia, Canada 2003.
36. Ronning M. Coding and Classification in drug statistics - From national to global applications. Norwegian J Epidemiol 2001;11:37-40.
37. 2003 ATC Index with DDDs. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2003.
38. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-1969.
39. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
40. Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents and Supplements [electronic version]. Department of Health and Human Services (DHHS); 2003. August 8, aidsinfo.nih.gov/guidelines (Last accessed August 8, 2003).
41. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus [electronic version]. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA), 2003. aidsinfo.nih.gov/guidelines (Last accessed August 8, 2003).
42. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
43. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
44. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
45. Eggen AE. Pattern of drug use in a general population - Prevalence and predicting factors: the Tromso study. Int J Epidemiol 1994;23:1262-1272.
46. Simoni-Wastila L. Gender and psychotropic drug use. Med Care 1998;36:88-94.
47. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: Evidence for undertreatment in women and the elderly. Arch Intern Med 1996;156:799-805.
48. Singh N, Squier C, Sivek C, Nguyen MH, Wagener M, Yu VL. Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Arch Intern Med 1996;156:197-201.
49. Fogelman I, Lim L, Bassett R, et al. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). J Acquir Immune Defic Syndr 1994;7:1057-1063.
50. Office of Applied Studies. Results from the 2001 National Household Survey on drug abuse: Volume II. Technical appendices and selected data tables. NHSDA Series H-18. DHHS Pub. No. (SMA) 02-3759. Rockville, MD: Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, 2002.
51. Marijuana and Medicine Assessing the Science Base [electronic version]. Washington, D.C.: 1999. Washington, DC: National Academy Press, 2003. http://books.nap.edu/htm/marimed (last accessed March 5, 2004).
52. Ogborne AC, Smart RG. Cannabis users in the general Canadian population. Subst Use Misuse 2000;35:301-311.
53. Hewitt RG, Parsa N, Gugino N. Women's health. The role of gender in HIV progression. AIDS Reader 2001;11:29-33.
54. Harrold LR, Lessard D, Yarzebski J, Gurwitz JH, Gore JM, Goldberg RJ. Age and sex differences in the treatment of patients with initial acute myocardial infarction: A community-wide perspective. Cardiology 2003;99:39-46.
55. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003;55:604-608.
56. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-1715.